Search for: "Novartis Pharmaceuticals Corp" Results 161 - 180 of 367
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
2 Feb 2012, 6:28 am
SmithKlineBeecham Corp., which involves the same issue of whether the FLSA's outside sales exemption applies to pharmaceutical representatives. [read post]
30 Jan 2012, 11:12 am by admin
District Judge Paul Crotty issued a preliminary approval of a $99 million settlement agreement between Novartis Pharmaceuticals Corp. and a class of more than 7,000 pharmaceutical sales representatives who allege that the company misclassified them as exempt from overtime pay. [read post]
27 Jan 2012, 6:00 am by Keith Reinfeld
SmithKline Beecham Corp., that held a proposed class of pharmaceutical sales representatives to be exempt from overtime pay pursuant to the “outside sales exemption. [read post]
16 Jan 2012, 4:00 am by Steve McConnell
Novartis Pharmaceuticals Corp., Nos. 09-6147, 09-6272, 09-6274, 2011 WL 3701816 (6th Cir. [read post]
5 Dec 2011, 8:59 am by Kara M. Maciel
SmithKline Beecham Corp., for example, rejected the argument that pharmaceutical sales representatives did not qualify for the Outside Sales exemption. [read post]
5 Dec 2011, 8:59 am by <a href=''>Kara M. Maciel</a>
SmithKline Beecham Corp., for example, rejected the argument that pharmaceutical sales representatives did not qualify for the Outside Sales exemption. [read post]
2 Dec 2011, 2:00 pm by Bexis
Novartis Pharmaceuticals Corp., ___ Fed. [read post]
1 Dec 2011, 10:34 am by Leigh Anne Benedic
SmithKline Beecham Corp., where it held that GlaxoSmithKline's PSRs were properly classified as exempt. [read post]
28 Nov 2011, 11:42 am by Jonathan H. Adler
SmithKline Beecham Corp., in which the Court will have to determine whether pharmaceutical sales representatives are subject to the “outside sales” exemption from the Fair Labor Standards Act’s overtime requirements. [read post]
25 Nov 2011, 5:00 am by Bexis
Novartis Pharmaceuticals Corp., 2011 WL 5835414, slip op. [read post]
4 Nov 2011, 4:09 am by John Hopkins
Novartis Pharmaceutical paid $422.5 million to settle claims it promoted its epilepsy drug, Trileptal, for off label uses. [read post]